UCB (OTCMKTS:UCBJY) Sees Large Volume Increase - Here's What Happened

Key Points

• UCB SA experienced a significant increase in trading volume, with approximately 94,998 shares traded on Monday, marking a 118% increase from the previous session.
• The Goldman Sachs Group has upgraded UCB’s stock rating to "strong-buy", contributing to an overall average rating of "Strong Buy" from analysts.
• UCB's stock price rose by 1.2%, closing at $117.24, following its trading activity and positive analyst sentiment.

UCB SA (OTCMKTS:UCBJY - Get Free Report) saw strong trading volume on Monday . 94,998 shares changed hands during trading, an increase of 118% from the previous session's volume of 43,591 shares.The stock last traded at $117.24 and had previously closed at $115.94.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded UCB to a "strong-buy" rating in a research report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Strong Buy".

UCB Trading Down 0.1%

The stock has a 50 day simple moving average of $105.49 and a two-hundred day simple moving average of $95.70. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.99 and a current ratio of 1.36.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.